-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Indivior Study Shows Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression In Chronic Opioid Users
Indivior Study Shows Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression In Chronic Opioid Users
Indivior PLC (OTCPK:INVVY) (LON:INDV) published modeling data examining the competitive interaction between buprenorphine, a treatment for opioid use disorder, and fentanyl, a potent synthetic opioid, to better understand how buprenorphine can reduce fentanyl-induced respiratory depression. The study entitled "Modelling buprenorphine reduction of fentanyl-induced respiratory depression" is available online and will appear in an upcoming print issue of JCI Insight, a peer-reviewed journal. The study was supported by Indivior.
This pharmacokinetic/pharmacodynamic study aimed at modeling the interaction of buprenorphine and fentanyl at the level of the mu-opioid receptor on minute ventilation under elevated carbon dioxide levels in opioid-naïve volunteers and chronic opioid users. Data used for modeling were from a clinical pharmacology study recently published in PLOS ONE. The main objective of the modeling was to characterize the effects of escalating intravenous fentanyl doses (0.25-0.70 mg/70 kg range in chronic opioid users) on respiratory depression compared to the intravenous infusion of either placebo or buprenorphine targeting plasma concentrations within the 0.2-5 ng/mL range.
Buprenorphine medications for opioid use disorder has been shown to reduce illicit opioid use and opioid-related mortality. This analysis describes another mechanism by which buprenorphine may reduce opioid overdose deaths. The modeling data indicate that buprenorphine plasma concentrations of 2 ng/mL and higher may have a protective effect against fentanyl-induced respiratory depression in chronic opioid users, with a reduced probability of apnea following exposure to high fentanyl doses.The model shows that when MOR occupancy by buprenorphine is sufficiently high, fentanyl is unable to activate the MOR and consequently will not cause additional respiratory depression on top of the mild respiratory effects of buprenorphine in that population.
"These modeling data show that buprenorphine plasma concentrations of 2 ng/mL and higher seem to have a protective effect against fentanyl-induced respiratory depression," stated Christian Heidbreder, PhD, chief scientific officer, Indivior. "Although the source study was conducted in a controlled setting and in a relatively small number of chronic opioid users, the ability of buprenorphine to reduce the risk of serious respiratory events triggered by fentanyl was demonstrated and warrants further investigation in a real-world setting."
Photo: Courtesy of Vladislav Muslakov on Unsplash
Related News
Indivior PLC (OTCPK:INVVY) (LON:INDV) published modeling data examining the competitive interaction between buprenorphine, a treatment for opioid use disorder, and fentanyl, a potent synthetic opioid, to better understand how buprenorphine can reduce fentanyl-induced respiratory depression. The study entitled "Modelling buprenorphine reduction of fentanyl-induced respiratory depression" is available online and will appear in an upcoming print issue of JCI Insight, a peer-reviewed journal. The study was supported by Indivior.
分割器PLC(OTCPK:INVVY)(LON:INV)已出版研究治療阿片類藥物使用障礙的丁丙諾啡和有效的合成阿片類藥物芬太尼之間的競爭相互作用的模擬數據,以更好地理解丁丙諾啡如何減輕芬太尼誘導的呼吸抑制。這項題為“丁丙諾啡減少芬太尼引起的呼吸抑制的模型”的研究可在網上獲得,並將發表在即將出版的同行評議期刊JCI Insight的印刷版上。這項研究得到了Indior的支持。
This pharmacokinetic/pharmacodynamic study aimed at modeling the interaction of buprenorphine and fentanyl at the level of the mu-opioid receptor on minute ventilation under elevated carbon dioxide levels in opioid-naïve volunteers and chronic opioid users. Data used for modeling were from a clinical pharmacology study recently published in PLOS ONE. The main objective of the modeling was to characterize the effects of escalating intravenous fentanyl doses (0.25-0.70 mg/70 kg range in chronic opioid users) on respiratory depression compared to the intravenous infusion of either placebo or buprenorphine targeting plasma concentrations within the 0.2-5 ng/mL range.
這項藥代動力學/藥效學研究旨在模擬在阿片類藥物單純志願者和慢性阿片類藥物使用者二氧化碳水平升高的情況下,丁丙諾啡和芬太尼在單位阿片受體水平上對分鐘通氣量的相互作用。用於建模的數據來自最近發表在《公共科學圖書館·綜合》上的一項臨牀藥理學研究。建模的主要目的是比較靜脈注射芬太尼劑量增加(慢性阿片類藥物使用者為0.25-0.70 mg/70公斤)與靜脈滴注安慰劑或丁丙諾啡對呼吸抑制的影響,目標血漿濃度在0.2-5 ng/毫升範圍內。
Buprenorphine medications for opioid use disorder has been shown to reduce illicit opioid use and opioid-related mortality. This analysis describes another mechanism by which buprenorphine may reduce opioid overdose deaths. The modeling data indicate that buprenorphine plasma concentrations of 2 ng/mL and higher may have a protective effect against fentanyl-induced respiratory depression in chronic opioid users, with a reduced probability of apnea following exposure to high fentanyl doses.The model shows that when MOR occupancy by buprenorphine is sufficiently high, fentanyl is unable to activate the MOR and consequently will not cause additional respiratory depression on top of the mild respiratory effects of buprenorphine in that population.
丁丙諾啡治療阿片使用障礙的藥物已被證明可以減少非法阿片使用和阿片相關死亡率。這項分析描述了丁丙諾啡可能減少阿片類藥物過量死亡的另一種機制。模擬數據表明,丁丙諾啡血漿濃度在2 ng/mL或更高時,可能對慢性阿片使用者芬太尼引起的呼吸抑制具有保護作用暴露於高劑量芬太尼後,呼吸暫停的可能性降低。該模型顯示,當丁丙諾啡的MOR佔有率足夠高時,芬太尼不能激活MOR,因此在該人羣中,除了丁丙諾啡輕微的呼吸作用外,芬太尼不會造成額外的呼吸抑制。
"These modeling data show that buprenorphine plasma concentrations of 2 ng/mL and higher seem to have a protective effect against fentanyl-induced respiratory depression," stated Christian Heidbreder, PhD, chief scientific officer, Indivior. "Although the source study was conducted in a controlled setting and in a relatively small number of chronic opioid users, the ability of buprenorphine to reduce the risk of serious respiratory events triggered by fentanyl was demonstrated and warrants further investigation in a real-world setting."
“這些模擬數據表明,丁丙諾啡的血漿濃度在2 ng/ml或更高時,似乎對芬太尼誘導的呼吸抑制有保護作用,”聲明説。克里斯蒂安·海德佈雷德,博士,Indior首席科學官。雖然來源研究是在受控環境下進行的,而且是在相對較少的慢性阿片類藥物使用者中進行的,但丁丙諾啡能夠降低由芬太尼引發的嚴重呼吸事件的風險是被證明的,因此需要在現實世界中進行進一步的研究。
Photo: Courtesy of Vladislav Muslakov on Unsplash
圖片:由弗拉迪斯拉夫·穆斯拉科夫在UnSplash上提供
Related News
相關新聞
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧